1:17-cv-00828 | Biogen MA Inc. v. Slayback Pharma LLC, et al | RPX Insight

Biogen MA Inc. v. Slayback Pharma LLC, et al DC CAFC
- 1:17-cv-00828
- D. Del.
- Judge: Maryellen Noreika
- Filed: 06/26/2017
- Closed: 09/22/2020
- Latest Docket Entry: 10/31/2022
- PACER
- Docket updated daily

1

Plaintiff

2

Defendants

2

Accused Products

1

Patent-in-Suit

1,185

Days in Litigation

Docket (51 Entries)

Biogen MA Inc. v. Slayback Pharma LLC, et al DC CAFC
- 1:17-cv-00828
- D. Del.
- Judge: Maryellen Noreika
- Filed: 06/26/2017
- Closed: 09/22/2020
- Latest Docket Entry: 10/31/2022
- PACER
- Docket updated daily

Docket (51 Entries)

Litigation Complaint | RPX Insight

View Complaint

Appeals

21-1078
21-1086

Cause of Action

Infringement

Market Sector

Biotech and Pharma

Court

District of Delaware

Assigned Judge

Maryellen Noreika

Outcome Summary

View Outcome Details

Validity and Enforceability Details

Infringement Details

Patent Information

Patents-in-Suit

Validity & Enforceability

US 8,399,514 B2

13 Details

Claim #	Claim Text	Outcome
1	A method of treating a subject in need of treatment for multiple sclerosis comprising orally administering to the subject in need thereof a pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof, and (b) one or more pharmaceutically acceptable excipients, wherein the therapeutically effective amount of dimethyl fumarate, monomethyl fumarate, or a combination thereof is about 480 mg per day. view more	Invalid Entry 18
2	The method of claim 1, wherein the pharmaceutical composition is administered in the form of a tablet, a suspension, or a capsule.	Invalid Entry 18
3	The method of claim 1, wherein the therapeutically effective amount is administered in separate administrations of 2, 3, 4, or 6 equal doses.	Invalid Entry 18
4	The method of claim 3, wherein the therapeutically effective amount is administered in separate administrations of 2 equal doses.	Invalid Entry 18
6	The method of claim 1, wherein the pharmaceutical composition consists essentially of dimethyl fumarate and one or more pharmaceutically acceptable excipients.	Invalid Entry 18
8	The method of claim 1, wherein the pharmaceutical composition is administered to the subject for at least 12 weeks.	Invalid Entry 18
9	The method of claim 6, wherein the therapeutically effective amount is administered to the subject in 2 equal doses.	Invalid Entry 18
10	The method of claim 9, wherein the therapeutically effective amount is administered to the subject for at least 12 weeks.	Invalid Entry 18
11	A method of treating a subject in need of treatment for multiple sclerosis consisting essentially of orally administering to the subject about 480 mg per day of dimethyl fumarate, monomethyl fumarate, or a combination thereof.	Invalid Entry 18
12	The method of claim 11, wherein about 480 mg of dimethyl fumarate per day is administered to the subject.	Invalid Entry 18
13	The method of claim 12, wherein the dimethyl fumarate is administered in separate administrations of 2 equal doses.	Invalid Entry 18
15	A method of treating a subject in need of treatment for multiple sclerosis comprising orally administering to the subject pharmaceutical composition consisting essentially of (a) a therapeutically effective amount of dimethyl fumarate and (b) one or more pharmaceutically acceptable excipients, wherein the therapeutically effective amount of dimethyl fumarate is about 480 mg per day. view more	Invalid Entry 18
16	The method of claim 15, wherein the dimethyl fumarate is administered in separate administrations of 2 equal doses.	Invalid Entry 18